Emerging aspects of pharmacotherapy for obesity and metabolic syndrome

被引:31
作者
Nisoli, E
Carruba, MO
机构
[1] Univ Milan, Dept Preclin Sci, Ctr Study & Res Obes, L Sacco Hosp,LITA Vialba, I-20157 Milan, Italy
[2] Ist Auxol Italiano, Milan, Italy
关键词
obesity; anti-obesity drugs; metabolic fitness; obesity-related disorders; metabolic syndrome; leptin; thermogenic drugs; mitochondria;
D O I
10.1016/j.phrs.2004.02.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic. Obese patients are at higher risk from coronary artery disease, hypertension, hyperlipidemia, diabetes mellitus, cancers, cerebrovascular accidents, osteoarthritis, restrictive pulmonary disease, and steep apnoea. In particular, visceral fat accumulation is usually accompanied by insulin resistance or type 2 diabetes mellitus, hypertension, hypertriglyceridemia, high uremic acid levels, low high density lipoprotein (HDL) cholesterol to define a variously named syndrome or metabolic syndrome. Metabolic syndrome is now considered a major cardiovascular risk factor in a large percentage of population in worldwide. Both obesity and metabolic syndrome are particularly challenging clinical conditions to treat because of their complex pathophysiological basis. Indeed, body weight represents the integration of many biological and environmental components and relationships among fat and glucose tolerance or blood pressure are not completely understood. Efforts to develop innovative anti-obesity drugs, with benefits for metabolic syndrome, have been recently intensified. In general two distinct strategies can be adopted: first, to reduce energy intake; second, to increase energy expenditure. Here we review some among the most promising avenues in these two fields of drug therapy of obesity and, consequently, of metabolic syndrome. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:453 / 469
页数:17
相关论文
共 161 条
[1]   Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei [J].
Abbott, CR ;
Rossi, M ;
Wren, AM ;
Murphy, KG ;
Kennedy, AR ;
Stanley, SA ;
Zollner, AN ;
Morgan, DGA ;
Morgan, I ;
Ghatei, MA ;
Small, CJ ;
Bloom, SR .
ENDOCRINOLOGY, 2001, 142 (08) :3457-3463
[2]   CANNABIS - EFFECTS ON HUNGER AND THIRST/EUM OF [J].
ABEL, EL .
BEHAVIORAL BIOLOGY, 1975, 15 (03) :255-281
[3]   Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity [J].
Air, EL ;
Strowski, MZ ;
Benoit, SC ;
Conarello, SL ;
Salituro, GM ;
Guan, XM ;
Liu, K ;
Woods, SC ;
Zhang, BB .
NATURE MEDICINE, 2002, 8 (02) :179-183
[4]   Intracerebroventricular CART peptide reduces food intake and alters motor behavior at a hindbrain site [J].
Aja, S ;
Sahandy, S ;
Ladenheim, EE ;
Schwartz, GJ ;
Moran, TH .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (06) :R1862-R1867
[5]   SPECIFIC-INHIBITION OF ENDOGENOUS NEUROPEPTIDE-Y SYNTHESIS IN ARCUATE NUCLEUS BY ANTISENSE OLIGONUCLEOTIDES SUPPRESSES FEEDING-BEHAVIOR AND INSULIN-SECRETION [J].
AKABAYASHI, A ;
WAHLESTEDT, C ;
ALEXANDER, JT ;
LEIBOWITZ, SF .
MOLECULAR BRAIN RESEARCH, 1994, 21 (1-2) :55-61
[6]  
[Anonymous], 1983, Diabetologia, V24, P404
[7]  
[Anonymous], 2001, The Surgeon Generals call to action to prevent and decrease overweight and obesity
[8]  
ARCH JRS, 1984, INT J OBESITY, V8, P1
[9]   Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet [J].
Asnicar, MA ;
Smith, DP ;
Yang, DD ;
Heiman, ML ;
Fox, N ;
Chen, YF ;
Hsiung, HM ;
Köster, A .
ENDOCRINOLOGY, 2001, 142 (10) :4394-4400
[10]   CONTRIBUTION OF BAT AND SKELETAL-MUSCLE TO THERMOGENESIS INDUCED BY EPHEDRINE IN MAN [J].
ASTRUP, A ;
BULOW, J ;
MADSEN, J ;
CHRISTENSEN, NJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (05) :E507-E515